Edwards Lifesciences
921 hedge funds and large institutions have $32B invested in Edwards Lifesciences in 2019 Q2 according to their latest regulatory filings, with 95 funds opening new positions, 296 increasing their positions, 357 reducing their positions, and 83 closing their positions.
33% more call options, than puts
Call options by funds: $224M | Put options by funds: $169M
14% more first-time investments, than exits
New positions opened: 95 | Existing positions closed: 83
0% less funds holding
Funds holding: 922 → 921 (-1)
5% less capital invested
Capital invested by funds: $33.6B → $32B (-$1.61B)
3.87% less ownership
Funds ownership: 253.32% → 249.45% (-3.9%)
16% less funds holding in top 10
Funds holding in top 10: 25 → 21 (-4)
17% less repeat investments, than reductions
Existing positions increased: 296 | Existing positions reduced: 357
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
N
Nuveen
Charlotte,
North Carolina
|
+$708M |
| 2 |
Capital International Investors
Los Angeles,
California
|
+$508M |
| 3 |
Capital Research Global Investors
Los Angeles,
California
|
+$276M |
| 4 |
HM
HealthCor Management
New York
|
+$113M |
| 5 |
Bessemer Group
Woodbridge,
New Jersey
|
+$91.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$525M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$294M |
| 3 |
BlackRock
New York
|
-$127M |
| 4 |
VOYA Investment Management
Atlanta,
Georgia
|
-$117M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
-$110M |
EW Hedge Fund Activity: Q2 2019 in Review
921 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Edwards Lifesciences (EW) for Q2 2019, worth a combined $32B — down 4.8% from $33.6B a quarter earlier.
Buyers outnumbered sellers: 95 funds opened new EW positions and 83 closed out — a net gain of 12 holders — while 296 added to existing stakes and 357 trimmed.
The largest buyer was Nuveen, adding an estimated $708M. The largest seller was Vanguard Group, cutting an estimated $525M.
- 921 institutional investors held Edwards Lifesciences (EW) as of Q2 2019, down from 922 in Q1 2019.
- Funds reported $32B of Edwards Lifesciences stock for Q2 2019, down 4.8% quarter-over-quarter.
- 95 funds opened new Edwards Lifesciences positions in Q2 2019 and 83 closed out, a net change of +12 holders.
- The largest Edwards Lifesciences buyer in Q2 2019 was Nuveen, an estimated $708M added.
- The largest Edwards Lifesciences seller in Q2 2019 was Vanguard Group, an estimated $525M sold.
Based on aggregated 13F filings for Q2 2019.